Non-diabetic patients with a BMI of ≥30, or ≥27 with comorbidities, lost an average of 15% of their body weight in 1 year in a 68-week clinical trial evaluating 2.4 mg semaglutide, when combined with a reduced-calorie diet and increased physical activity.
National GLP-1 shortages through 2023. See more
Join 150,000+ Ro weight loss patients
Wegovy® prescribed online for weight loss
Lose 15% of your body weight on average in 1 year*
Genuine, FDA-approved treatment
Helps you feel full faster, longer
*In clinical trials studying Saxenda and Wegovy for obesity (BMI ≥30) and overweight (BMI ≥27) with at least one weight-related condition, non-diabetics who completed the trials lost an average of 9% and 15% of their body weight, respectively, when paired with diet and exercise (compared to 3.5% and 2.4% on diet and exercise alone). Some patients may start on Saxenda and then switch to Wegovy if accessible and clinically appropriate.
Safety info: GLP-1 medications are used to treat obesity or overweight (with weight-related problems), along with diet and exercise. They may have serious side effects, including possible thyroid tumors. Do not use if you or your family have a history of a type of thyroid cancer called MTC or MEN 2. See more serious warnings & safety info
There’s a reason everyone is talking about Wegovy. It works!
On average, people on Wegovy lose 15% of their weight in a year*.
*Patients without diabetes but with a BMI of ≥30, or ≥27 with comorbidities, lost an average of 15% of their body weight in 1 year in a 68-week clinical trial evaluating 2.4 mg semaglutide, when combined with a reduced-calorie diet and increased physical activity. Wegovy is FDA-approved for weight loss. Ozempic is FDA-approved for type 2 diabetes treatment, but may be prescribed for weight loss.
Enter your current weight (lbs):
Weight you could lose (lbs):
Meet the Ro Ambassadors who inspired the Body Program
Lost 40 lbs in 11 months
“I have never felt better. I have never had more energy. This medication changed my life.”
Lost 30 lbs in 1 year
“I started losing weight almost immediately. To me, truly, this has been a game-changer.”
Wegovy is semaglutide (a GLP-1) that may be prescribed for weight loss, if appropriate. It’s a once-weekly shot that works by mimicking your body’s natural hormones, helping you feel fuller faster and for longer.
Medication is not included in the cost of the Body Program. But don’t worry, our insurance concierge partners explore all options to help get you covered. Wegovy is FDA-approved for weight loss.
In Wegovy clinical trials, patients lost an average of 15% of their body weight*
"Is using medication to lose weight cheating?"
Dr. Steve Silvestro, Ro
Which GLP-1 is right for you?
Semaglutide injection was first approved under the brand name Ozempic in 2017 as a treatment for type 2 diabetes. In 2021, the FDA approved the drug at a different dosage under the brand name Wegovy as a weight loss medication. Doctors often, using their medical judgment and discretion, prescribe both for weight loss. Liraglutide injection was FDA approved for weight loss in 2014 under the brand name Saxenda.
All three medications are GLP-1s, but there are some key differences between them.
*Patients without diabetes but with a BMI of ≥30, or ≥27 with comorbidities, lost an average of 15% of their body weight in 1 year in a 68-week clinical trial evaluating 2.4 mg semaglutide, when combined with a reduced-calorie diet and increased physical activity.
Our insurance concierge partners will work to find you coverage for medication.
Here's how they'll do it:
How it works
We help you lose weight by pairing revolutionary medication with coaching, care, and healthy lifestyle changes to make it last.
Thousands of people are losing weight with GLP-1 medications
Hear from real Ro members who are hitting their weight loss goals through the Body Program. These Body Program members were paid for sharing their stories.
“I’ve had some pretty amazing success. I’m down 15 pounds and I couldn’t be happier."
Sonia, Ro Member
“It's really helping handle my cravings better, which is what I really like about this program."
James, Ro Member
“It was like a switch once I started the medication, I just wasn’t so obsessed with food.”
Chaleeta, Ro Member
What is Wegovy?
Wegovy is a brand-name version of the generic medication semaglutide, which is a type of medication called a glucagon-like peptide 1 receptor agonist. Instead of that tongue-twister of a name, we call these medications “GLP-1s” for short. Wegovy is FDA-approved and clinically proven to help with weight loss. How? It acts like a natural hormone your body uses to regulate blood sugar and appetite—key steps in resetting your biological set point to help you maintain a new, lower weight. In fact, in the pivotal clinical trial people who combined Wegovy with lifestyle changes lost an average of 9% of their body weight after 20 weeks, and 14.9% after 68 weeks. Learn more about Wegovy and weight loss.
How does Wegovy work?
Wegovy works by mimicking the hormone GLP-1, which slows digestion and helps your brain regulate appetite by reducing hunger sensations. As your digestion slows, you may feel full longer and therefore eat less, which can lead to weight loss.
What is Wegovy’s dosing?
Wegovy dosing starts out low, then gradually increases over the first few months until a steady dose is reached. If prescribed, your Ro-affiliated provider will work with you to find the schedule and dosing that’s right for you. As an example, your provider may start you out on the lowest dose, 0.25 mg injected once weekly for the first month and slowly ramp you up to the maximum dose of 2.4 mg once weekly over the course of several months. This will depend upon your specific situation and your provider’s guidance.
How do you take Wegovy?
Wegovy comes in a prefilled injection pen. If prescribed, you (or someone in your household) will administer the injection under the skin of your stomach, thigh, or arm once a week. While a routine injection may sound intimidating, the Wegovy pen uses a tiny needle designed to minimize discomfort. You’ll also receive clear instructions on using the injection pen, and your Ro-affiliated provider can offer additional advice.
How much weight can I expect to lose with GLP-1s?
In clinical trials, patients lost 15% of their body weight after 1 year, on average. This is based on the average weight loss in the three 68-week clinical trials of patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity.
How quickly do people lose weight with Wegovy?
In the STEP 4 clinical trial, people who combined Wegovy with a healthy diet and exercise lost an average of over 4% of their body weight by eight weeks. Those who reached a steady dose of 2.4 mg per week lost an average of 10.6% of their body weight in the first 20 weeks of treatment—and over 17% of their body weight within 68 weeks. Everyone responds to Wegovy differently, and if prescribed, your Ro-affiliated provider will work with you to get the best results for you. See if Wegovy is right for you here.
$145/month, $99 first month promo
Medication is prescribed only if appropriate.
Still have questions? We have answers.
Weight management tips from our experts
Reading time: 8 min
How much does Wegovy cost?
Reading time: 7 min
Wegovy or Ozempic for weight loss?
Reading time: 7 min
Wegovy shortage alternatives
Reading time: 7 min
What happens when you stop taking Wegovy?
Important safety information
Warning: Risk of Thyroid C-Cell Tumors
In studies with mice and rats, semaglutide (the active ingredient in Wegovy and Ozempic) caused thyroid tumors, including thyroid cancer. It is not known if Wegovy will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
Do not use Wegovy if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
What is the FDA-approved use of Wegovy?
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of:
30 kg/m2 or greater (obesity) or
27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).
Limitations of Use:
Wegovy should not be used in combination with other semaglutide-containing products or any other GLP-1 receptor agonist
The safety and efficacy of coadministration with other products for weight loss have not been established
Wegovy has not been studied in patients with a history of pancreatitis
Who should not use Wegovy?
Do not use Wegovy if:
You or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
You have a known allergic reaction to semaglutide (the active ingredient in Wegovy or Ozempic).
How should Wegovy be administered?
You can take Wegovy with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Your Ro-affiliated provider will guide you on a treatment regimen that may include an increase in dose every four weeks.
You should not change your dosing regimen or stop taking Wegovy as prescribed without discussing with your provider first.
What should I tell my Ro-affiliated provider before using Wegovy?
Wegovy has certain drug interactions. It’s important to tell your Ro-affiliated provider all of the medications you are currently taking, including prescription, over-the-counter medications, vitamins, and herbal and dietary supplements.
Some medications to watch out for include:
Medications used to treat type 1 or type 2 diabetes, including insulin or sulfonylureas (such as Amaryl or Glucotrol XL)
Wegovy causes a delay in gastric emptying, so it has the potential to impact the absorption of medications that are taken by mouth at the same time. Your provider can guide you on how to schedule your medications.
Other GLP-1 medications, including Ozempic, Saxenda, Victoza, Byetta, or Bydureon
If you’re using other products for weight loss, including dietary supplements
It’s important to share your entire medical history with your provider. In particular, tell your provider if you have a past history of:
Type 1 or type 2 diabetes
Suicidal thoughts or behavior
Tell your provider if you are pregnant, planning to become pregnant, or breastfeeding.
If you are pregnant: Wegovy should not be used during pregnancy. Based on animal studies, there may be potential risks to an unborn baby from exposure to Wegovy during pregnancy. There is no benefit to weight loss during pregnancy and it may cause harm to the unborn baby.
If you are a female or male of reproductive potential: Discontinue Wegovy at least 2 months before a planned pregnancy since the drug can stay in the bloodstream for a long time.
If you are breastfeeding: Wegovy was found in the milk of lactating rats. Tell your Ro-affiliated provider if you are breastfeeding before you start Wegovy.
Pregnancy registry: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to semaglutide (the active ingredient in Wegovy and Ozempic) during pregnancy. Pregnant women exposed to semaglutide and healthcare providers are encouraged to contact Novo Nordisk at 1-800-727-6500.
Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm, including, in some cases, death.
What are the most serious side effects that I or a caregiver should monitor for when taking Wegovy?
If you are experiencing a medical emergency, call 911 or seek immediate medical attention.
These serious side effects can occur with Wegovy. You or a caregiver should carefully monitor for these side effects, especially in the beginning of treatment and with dose changes.
Thyroid C-Cell Tumors: In mice and rats, semaglutide (the active ingredient in Wegovy and Ozempic) caused an increase in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether Wegovy causes thyroid C-cell tumors in humans. There were cases of MTC reported in patients who took liraglutide (the active ingredient in Victoza and Saxenda) after the drug was put on the market. Wegovy is contraindicated in patients with a family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
Inflammation of Pancreas (Acute Pancreatitis): Monitor for signs of acute pancreatitis, including severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting.
Acute Gallbladder Disease: Wegovy may cause gallbladder problems, including gallstones. Some gallbladder problems require surgery. Tell your provider right away if you have pain in your upper stomach, yellowing of skin or eyes (jaundice), fever, or clay-colored stools.
Low Blood Sugar (hypoglycemia): Wegovy lowers blood glucose. It can cause too low blood sugar in patients with type 2 diabetes who also take another glucose control medication. Monitor your blood sugar and watch out for signs of too low blood sugar such as dizziness, blurred vision, mood changes, sweating, or fast heartbeat.
Acute Kidney Injury: In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems to get worse. It is important for you to drink plenty of water to help reduce your chance of dehydration.
Serious Allergic Reactions: Stop using Wegovy right away if you experience symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, or fainting or feeling dizzy.
Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: If you have type 2 diabetes, tell your provider right away if you experience changes in vision.
Increase in Heart Rate: Tell your provider right away if you have a racing heartbeat while at rest.
Suicidal Behavior and Ideation: You should pay attention to any mental health changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you.
Never Share a Pen: Pen-sharing poses a risk of infection.
What are the most common side effects of Wegovy?
Hypoglycemia in patients with type 2 diabetes
Gastroesophageal reflux disease
You are encouraged to report negative side effects of prescription products: Contact Novo Nordisk Inc. at 1-833-934-6891 Contact FDA MedWatch at 1-800-FDA-1088 or visit www.fda.gov/medwatch
This information is not comprehensive. Please see the full Prescribing Information for complete safety information.